Disease modification in axial spondyloarthritis

Area of Science:

• Rheumatology
• Immunology
• Orthopedics

Background:

• Disease modification in axial spondyloarthritis (axSpA) targets both symptom improvement and altering the disease's natural course.
• A key goal is to slow or halt new bone formation, a hallmark of axSpA pathogenesis.
• Current therapies, including biologics and NSAIDs, demonstrate symptom-modifying effects.

Purpose of the Study:

• To review molecular mechanisms underlying new bone formation in axSpA.
• To assess the role of imaging in tracking disease progression and new bone formation.
• To identify clinical predictors of new bone formation and evaluate the disease-modifying potential of existing treatments.

Main Methods:

• Literature review focusing on molecular pathways of bone formation.
• Analysis of imaging study relevance for disease progression assessment.
• Synthesis of data on clinical predictors and treatment efficacy for disease modification.

Main Results:

• Evidence supports biologic therapies in improving spinal damage in axSpA.
• New bone formation is a central target for achieving disease modification.
• Understanding molecular mechanisms and clinical predictors is crucial for effective intervention.

Conclusions:

• Disease-modifying treatments for axSpA should aim to inhibit new bone formation.
• Biologics show promise in altering the structural progression of axSpA.
• Further research into targeted therapies is warranted to halt bone accrual and improve long-term outcomes.